Aclidinium bromide

Active ingredient description

Aclidinium bromide is a competitive, selective muscarinic receptor antagonist (also known as an anticholinergic), with a longer residence time at the M3 receptors than the M2 receptors. M3 receptors mediate contraction of airway smooth muscle. Inhaled aclidinium bromide acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
R03BB05
Aclidinium bromide
R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BB Anticholinergics
Discover more medicines within R03BB05

Medicines

Aclidinium bromide is the active ingredient of these drugs:

Drug
Countries
BRETARIS GENUAIR

Australia Austria Ireland Lithuania Netherlands

EKLIRA GENUAIR

Austria Cyprus Hong Kong Ireland Lithuania

TUDORZA GENUAIR

Canada

TUDORZA PRESSAIR

United States

Aclidinium bromide is also found within below combination drugs:

BRIMICA , DUAKLIR

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
BRETARIS GENUAIR Inhalation powder
Summary of product characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

UQW7UF9N91 - ACLIDINIUM BROMIDE

CAS registry number

320345-99-1 - aclidinium bromide

SNOMED-CT

703921008 - Aclidinium (substance)

703922001 - Aclidinium bromide (substance)

Next: Usage